ZA935111B
(en)
*
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935110B
(en)
*
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
GB9307491D0
(en)
*
|
1993-04-08 |
1993-06-02 |
Sandoz Ltd |
Organic compounds
|
USRE40596E1
(en)
*
|
1993-04-08 |
2008-12-02 |
Novartis Ag |
Rapamycin assay
|
US7279561B1
(en)
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
JPH08509499A
(ja)
|
1993-04-23 |
1996-10-08 |
アボツト・ラボラトリーズ |
ラパマイシン結合体及び抗体
|
USRE37421E1
(en)
|
1993-07-16 |
2001-10-23 |
Smithkline Beecham Corporation |
Rapamycin derivatives
|
SI1033128T2
(sl)
*
|
1993-09-28 |
2012-02-29 |
Scherer Gmbh R P |
Izdelava mehke Ĺľelatinaste kapsule
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
JP4105761B2
(ja)
*
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン(マクロライド)の半合成類似体免疫調節剤
|
WO1995016691A1
(en)
*
|
1993-12-17 |
1995-06-22 |
Sandoz Ltd. |
Rapamycin derivatives useful as immunosuppressants
|
GB9405350D0
(en)
*
|
1994-03-18 |
1994-05-04 |
Sandoz Ltd |
Organic compounds
|
CZ289773B6
(cs)
*
|
1994-10-26 |
2002-04-17 |
Novartis Ag |
Farmaceutický prostředek pro místní aplikaci
|
US7205279B2
(en)
*
|
1995-10-25 |
2007-04-17 |
Novartis Ag |
Pharmaceutical compositions
|
MY129435A
(en)
|
1994-10-26 |
2007-04-30 |
Novartis Ag |
Pharmaceutical microemulsion preconcentrates
|
US5561138A
(en)
*
|
1994-12-13 |
1996-10-01 |
American Home Products Corporation |
Method of treating anemia
|
GB9618952D0
(en)
*
|
1996-09-11 |
1996-10-23 |
Sandoz Ltd |
Process
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
CA2219659C
(en)
|
1995-06-09 |
2008-03-18 |
Novartis Ag |
Rapamycin derivatives
|
FR2736550B1
(fr)
*
|
1995-07-14 |
1998-07-24 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
|
US5780462A
(en)
*
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
GB9601120D0
(en)
*
|
1996-01-19 |
1996-03-20 |
Sandoz Ltd |
Organic compounds
|
GB9606452D0
(en)
*
|
1996-03-27 |
1996-06-05 |
Sandoz Ltd |
Organic compounds
|
KR100616020B1
(ko)
*
|
1996-03-27 |
2007-01-31 |
노파르티스 아게 |
맥관장애및이종이식술에서의라파마이신유도체의용도
|
NZ333657A
(en)
*
|
1996-07-30 |
2000-05-26 |
Novartis Ag |
A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
WO1998009970A2
(en)
*
|
1996-09-09 |
1998-03-12 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
GB9624038D0
(en)
*
|
1996-11-19 |
1997-01-08 |
Sandoz Ltd |
Organic compounds
|
US6306166B1
(en)
*
|
1997-08-13 |
2001-10-23 |
Scimed Life Systems, Inc. |
Loading and release of water-insoluble drugs
|
PT1421939E
(pt)
*
|
1998-03-26 |
2010-07-12 |
Astellas Pharma Inc |
Preparaão da libertaão sustentada de um composto de macrëlido como tracolimus
|
US20050031611A1
(en)
*
|
1998-05-08 |
2005-02-10 |
Beth Israel Deaconess Medical Center |
Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
|
AU5487499A
(en)
*
|
1998-08-17 |
2000-03-06 |
American Home Products Corporation |
Photocyclized rapamycins
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
GB9826882D0
(en)
*
|
1998-12-07 |
1999-01-27 |
Novartis Ag |
Organic compounds
|
US7276506B2
(en)
*
|
1998-12-28 |
2007-10-02 |
4 Aza Bioscience Nv |
Immunosuppressive effects of pteridine derivatives
|
US6946465B2
(en)
*
|
1999-02-02 |
2005-09-20 |
4 Aza Bioscience Nv |
Immunosuppressive effects of pteridine derivatives
|
US7063857B1
(en)
|
1999-04-30 |
2006-06-20 |
Sucampo Ag |
Use of macrolide compounds for the treatment of dry eye
|
ATE474590T1
(de)
|
1999-05-10 |
2010-08-15 |
Paolo Brenner |
Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
PT1210350E
(pt)
*
|
1999-08-18 |
2004-10-29 |
Wyeth Corp |
Esteres de sdz-rad soluveis em agua
|
CA2383451A1
(en)
|
1999-08-24 |
2001-03-01 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
US7067526B1
(en)
|
1999-08-24 |
2006-06-27 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US6790228B2
(en)
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
DE60142677D1
(de)
|
2000-01-14 |
2010-09-09 |
Univ Pennsylvania |
O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen
|
GB0008785D0
(en)
|
2000-04-10 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
US8236048B2
(en)
|
2000-05-12 |
2012-08-07 |
Cordis Corporation |
Drug/drug delivery systems for the prevention and treatment of vascular disease
|
US6670355B2
(en)
*
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
ES2228932T3
(es)
|
2000-08-11 |
2005-04-16 |
Wyeth |
Procedimiento de tratamiento del carcinoma positivo de estrogenos.
|
DK1319008T3
(da)
|
2000-09-19 |
2009-02-09 |
Wyeth Corp |
Vandoplöselige rapamycinestere
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
JP5100951B2
(ja)
|
2000-09-29 |
2012-12-19 |
コーディス・コーポレイション |
被覆医用器具
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
AU2005201004A1
(en)
*
|
2001-02-19 |
2005-03-24 |
Novartis Ag |
Cancer treatment
|
AU2011226833B9
(en)
*
|
2001-02-19 |
2014-07-03 |
Novartis Ag |
Cancer treatment
|
AU2016206379B2
(en)
*
|
2001-02-19 |
2017-09-14 |
Novartis Ag |
Cancer Treatment
|
EP2762140B1
(en)
|
2001-02-19 |
2017-03-22 |
Novartis AG |
Treatment of solid brain tumours with a rapamycin derivative
|
TWI296196B
(en)
*
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
TWI233359B
(en)
*
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
WO2003004098A1
(en)
|
2001-07-06 |
2003-01-16 |
Sucampo Ag |
Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
|
ATE445838T1
(de)
|
2001-07-25 |
2009-10-15 |
Raptor Pharmaceutical Inc |
Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
WO2003043650A1
(en)
*
|
2001-11-21 |
2003-05-30 |
Sucampo Ag |
Use of fk506 and analogues for treating allergic diseases
|
EA008379B1
(ru)
|
2002-02-01 |
2007-04-27 |
Ариад Джин Терапьютикс, Инк. |
Фосфорсодержащие соединения и их применения
|
US20030176455A1
(en)
*
|
2002-03-13 |
2003-09-18 |
Wyeth |
Method of inhibiting cell death
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
DK1505959T3
(da)
|
2002-05-16 |
2009-02-23 |
Novartis Ag |
Anvendelse af EDG-receptorbindingsmidler ved cancer
|
EP2277898A3
(en)
|
2002-07-16 |
2011-06-01 |
Biotica Technology Limited |
Rapamycin analogues
|
ATE385795T1
(de)
|
2002-07-30 |
2008-03-15 |
Wyeth Corp |
Parenterale formulierungen mit einem rapamycin hydroxyester
|
EP1539157B1
(en)
|
2002-09-18 |
2013-08-21 |
Trustees Of The University Of Pennsylvania |
Rapamycin for use in inhibiting or preventing choroidal neovascularization
|
BR0314760A
(pt)
|
2002-09-24 |
2005-07-26 |
Novartis Ag |
Compostos orgânicos
|
AU2003293529A1
(en)
|
2002-12-16 |
2004-07-29 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
ATE457716T1
(de)
|
2002-12-30 |
2010-03-15 |
Angiotech Int Ag |
Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
|
AR042938A1
(es)
*
|
2003-02-06 |
2005-07-06 |
Wyeth Corp |
Uso del cci-779 en el tratamiento de la fibrosis hepatica
|
US20090093875A1
(en)
|
2007-05-01 |
2009-04-09 |
Abbott Laboratories |
Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
|
AR043504A1
(es)
*
|
2003-03-17 |
2005-08-03 |
Novartis Ag |
Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
|
GB0307867D0
(en)
*
|
2003-04-04 |
2003-05-14 |
Novartis Ag |
Pharmaceutical composition
|
US20070155771A1
(en)
*
|
2003-04-11 |
2007-07-05 |
David Rubinsztein |
Methods and means for treating protein conformational disorders
|
DK1615640T3
(da)
*
|
2003-04-22 |
2007-03-12 |
Wyeth Corp |
Antineoplastiske sammensætninger
|
US7160867B2
(en)
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
AU2004255340B2
(en)
*
|
2003-07-08 |
2008-05-01 |
Novartis Ag |
Use of rapamycin and rapamycin derivatives for the treatment of bone loss
|
CA2534549A1
(en)
*
|
2003-09-12 |
2005-03-24 |
4 Aza Bioscience Nv |
Pteridine derivatives for the treatment of septic shock and tnf-.alpha.-related diseases.
|
CA2539324A1
(en)
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
US20070032477A1
(en)
*
|
2003-10-17 |
2007-02-08 |
Waer Mark J A |
Pteridine derivatives useful for making pharmaceutical compositions
|
US7220755B2
(en)
*
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
US9114198B2
(en)
|
2003-11-19 |
2015-08-25 |
Advanced Cardiovascular Systems, Inc. |
Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
|
GB0327840D0
(en)
*
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
ATE418559T1
(de)
|
2004-03-01 |
2009-01-15 |
Terumo Corp |
Verfahren zur herstellung von o-alkylierten rapamycinderivaten
|
JP4716280B2
(ja)
*
|
2004-03-01 |
2011-07-06 |
テルモ株式会社 |
O−アルキル化ラパマイシン誘導体の製造法
|
EP1730525B1
(en)
|
2004-03-10 |
2013-06-19 |
Seradyn, Inc. |
Immunoassays for everolimus
|
AR047988A1
(es)
*
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
US8551512B2
(en)
*
|
2004-03-22 |
2013-10-08 |
Advanced Cardiovascular Systems, Inc. |
Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
|
US8778014B1
(en)
|
2004-03-31 |
2014-07-15 |
Advanced Cardiovascular Systems, Inc. |
Coatings for preventing balloon damage to polymer coated stents
|
JP2007532655A
(ja)
*
|
2004-04-14 |
2007-11-15 |
ワイス |
ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン42−エステルおよびジカルボン酸とのfk−50632−エステルの調製プロセス
|
EP1740710A1
(en)
*
|
2004-04-27 |
2007-01-10 |
Wyeth |
Labeling of rapamycin using rapamycin-specific methylases
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
US8709469B2
(en)
|
2004-06-30 |
2014-04-29 |
Abbott Cardiovascular Systems Inc. |
Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
WO2006026531A1
(en)
*
|
2004-08-27 |
2006-03-09 |
Cordis Corporation |
Solvent free amorphous rapamycin
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
US7901451B2
(en)
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US8313763B2
(en)
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
WO2006041942A2
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
WO2006050461A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Wyeth |
Use of an mtor inhibitor in treatment of uterine leiomyoma
|
US8021849B2
(en)
|
2004-11-05 |
2011-09-20 |
Siemens Healthcare Diagnostics Inc. |
Methods and kits for the determination of sirolimus in a sample
|
WO2006053754A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Novartis Ag |
COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
|
WO2006071966A2
(en)
*
|
2004-12-29 |
2006-07-06 |
The Brigham And Women's Hospital, Inc. |
Rapamycin compounds in the treatment of neurofibromatosis type 1
|
BRPI0608152A2
(pt)
|
2005-02-09 |
2009-11-10 |
Macusight Inc |
formulações para tratamento ocular
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
GB0503936D0
(en)
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
US7241771B2
(en)
|
2005-03-07 |
2007-07-10 |
Wyeth |
Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
|
GB0504994D0
(en)
*
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
KR20070116868A
(ko)
|
2005-03-11 |
2007-12-11 |
바이오티카 테크놀로지 리미티드 |
39데스메톡시라파마이신 및 그 유사체의 의학적 용도
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
US7189582B2
(en)
|
2005-04-27 |
2007-03-13 |
Dade Behring Inc. |
Compositions and methods for detection of sirolimus
|
EP2671508B1
(en)
|
2005-04-28 |
2020-09-16 |
Proteus Digital Health, Inc. |
Pharma-informatics system
|
MX2007015083A
(es)
*
|
2005-05-31 |
2008-01-17 |
Novartis Ag |
Combinacion de inhibidores de hmg-coa-reductasa e inhibidores de mtor.
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
WO2007011708A2
(en)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
KR101406415B1
(ko)
|
2005-07-15 |
2014-06-19 |
미셀 테크놀로지즈, 인코포레이티드 |
제어된 형태의 약물 분말을 함유하는 중합체 코팅
|
MX2008000897A
(es)
|
2005-07-20 |
2008-03-18 |
Novartis Ag |
Combinacion de una pirimidil-amino-benzamida y un inhibidor de cinasa mtor.
|
EP1912675B1
(en)
|
2005-07-25 |
2014-02-12 |
Emergent Product Development Seattle, LLC |
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
CA2621083C
(en)
|
2005-08-30 |
2017-04-11 |
University Of Miami |
Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
|
EP1776970A1
(en)
|
2005-10-12 |
2007-04-25 |
Albert Schömig |
Implant with multiple coating
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
GB0523659D0
(en)
*
|
2005-11-21 |
2005-12-28 |
Novartis Ag |
Organic compounds
|
EP1962819A1
(en)
*
|
2005-12-20 |
2008-09-03 |
Wyeth |
Control of cci-779 dosage form stability through control of drug substance impurities
|
AU2007204410A1
(en)
*
|
2006-01-12 |
2007-07-19 |
Novartis Ag |
Combination of mTOR inhibitor and antipolate compound
|
US20070173923A1
(en)
*
|
2006-01-20 |
2007-07-26 |
Savage Douglas R |
Drug reservoir stent
|
GB0601406D0
(en)
*
|
2006-01-24 |
2006-03-08 |
Novartis Ag |
Organic Compounds
|
ES2672627T3
(es)
*
|
2006-02-02 |
2018-06-15 |
Novartis Ag |
Tratamiento de la esclerosis tuberosa
|
CA2635797C
(en)
|
2006-02-09 |
2015-03-31 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
US7678901B2
(en)
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
BRPI0708562A2
(pt)
*
|
2006-03-07 |
2011-06-07 |
Wyeth Corp |
processos para preparar conjugados de polietileno glicor de macrolìdeos imunossupressores, um macrolìdeo imunossupressor peguilado, uma rapamicina peguilada, um everolimus peguilado, um cci-779 peguilado e um tacrolimus peguilado, e, produto
|
WO2007112052A2
(en)
|
2006-03-23 |
2007-10-04 |
Macusight, Inc. |
Formulations and methods for vascular permeability-related diseases or conditions
|
PL2019657T3
(pl)
|
2006-04-26 |
2015-10-30 |
Micell Technologies Inc |
Powłoki zawierające wiele leków
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
GB0609963D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
GB0609962D0
(en)
*
|
2006-05-19 |
2006-06-28 |
Biotica Tech Ltd |
Novel compounds
|
EP2040758A4
(en)
*
|
2006-06-30 |
2014-09-17 |
Interface Biologics Inc |
BIORESPONSIVE POLYMERS
|
WO2008009079A2
(en)
*
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
Substituted pteridines useful for the treatment and prevention of viral infections
|
WO2008009078A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
WO2008016633A2
(en)
*
|
2006-08-02 |
2008-02-07 |
Ariad Gene Therapeutics, Inc. |
Combination therapy
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
US10695327B2
(en)
|
2006-09-13 |
2020-06-30 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
WO2008033956A2
(en)
*
|
2006-09-13 |
2008-03-20 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
US8088789B2
(en)
|
2006-09-13 |
2012-01-03 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
CA2663377A1
(en)
|
2006-09-18 |
2008-03-27 |
Raptor Pharmaceutical Inc. |
Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
|
US20080097591A1
(en)
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
*
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
WO2008065887A1
(fr)
|
2006-11-27 |
2008-06-05 |
Terumo Kabushiki Kaisha |
Procédé de fabrication d'un dérivé de rapamycine o-alkylé, et dérivé de rapamycine o-alkylée
|
JP5603598B2
(ja)
|
2007-01-08 |
2014-10-08 |
ミセル テクノロジーズ、インコーポレイテッド |
生物分解層を有するステント
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
EP2491962A1
(de)
|
2007-01-21 |
2012-08-29 |
Hemoteq AG |
Medizinprodukt zur Behandlung von Verschlüssen von Körperdurchgängen und zur Prävention drohender Wiederverschlüsse
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
TW200845960A
(en)
*
|
2007-04-05 |
2008-12-01 |
Wyeth Corp |
Wortmannin-rapalog conjugate and uses thereof
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
US9192697B2
(en)
|
2007-07-03 |
2015-11-24 |
Hemoteq Ag |
Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
|
WO2009043174A1
(en)
|
2007-10-05 |
2009-04-09 |
Interface Biologics Inc. |
Oligofluorinated cross-linked polymers and uses thereof
|
EP2214748B1
(en)
|
2007-10-19 |
2016-12-07 |
Interface Biologics Inc. |
Self-eliminating coatings
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
EP2219700B1
(en)
|
2007-11-14 |
2024-03-20 |
Biosensors International Group, Ltd. |
Automated coating apparatus and method
|
WO2009089549A1
(en)
|
2008-01-11 |
2009-07-16 |
Massachusetts Eye & Ear Infirmary |
Conditional-stop dimerizable caspase transgenic animals
|
WO2009114010A1
(en)
*
|
2008-03-11 |
2009-09-17 |
Elixir Medical Corporation |
Macrocyclic lactone compounds and methods for their use
|
US20100048524A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
EP2278966B1
(en)
|
2008-03-21 |
2019-10-09 |
The University of Chicago |
Treatment with opioid antagonists and mtor inhibitors
|
JP6013733B2
(ja)
|
2008-04-11 |
2016-10-25 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Cd37免疫治療薬および二機能性化学療法薬とのその組合せ
|
US20110098241A1
(en)
*
|
2008-04-14 |
2011-04-28 |
Poniard Pharmaceuticals, Inc. |
Rapamycin analogs as anti-cancer agents
|
AU2009251504B2
(en)
|
2008-04-17 |
2013-09-05 |
Micell Technologies, Inc. |
Stents having bioabsorbable layers
|
KR20160131126A
(ko)
|
2008-06-20 |
2016-11-15 |
노파르티스 아게 |
다발성 경화증을 치료하기 위한 소아용 조성물
|
US8765162B2
(en)
|
2008-06-30 |
2014-07-01 |
Abbott Cardiovascular Systems Inc. |
Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
|
CA2730995C
(en)
|
2008-07-17 |
2016-11-22 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2011009096A1
(en)
|
2009-07-16 |
2011-01-20 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US8092822B2
(en)
|
2008-09-29 |
2012-01-10 |
Abbott Cardiovascular Systems Inc. |
Coatings including dexamethasone derivatives and analogs and olimus drugs
|
JP2012504654A
(ja)
*
|
2008-10-03 |
2012-02-23 |
エリクシアー メディカル コーポレイション |
多環状ラクトン化合物およびその使用方法
|
EP2337788B1
(en)
|
2008-10-17 |
2016-03-23 |
Wisconsin Alumni Research Foundation |
Method of making biologically active alpha-beta peptides
|
US20120064143A1
(en)
|
2008-11-11 |
2012-03-15 |
The Board Of Regents Of The University Of Texas System |
Inhibition of mammalian target of rapamycin
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
EP2376088B1
(en)
|
2008-12-23 |
2017-02-22 |
Gilead Pharmasset LLC |
6-O-Substituted-2-amino-purine nucleoside phosphoramidates
|
WO2010084501A1
(en)
*
|
2009-01-21 |
2010-07-29 |
Biocon Limited |
A method for determination of sirolimus stability and process for preparing its stable form
|
AU2010210422A1
(en)
|
2009-02-05 |
2011-08-18 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
|
WO2010103130A2
(en)
|
2009-03-13 |
2010-09-16 |
Katholieke Universiteit Leuven, K.U.Leuven R&D |
Novel bicyclic heterocycles
|
JP2012522589A
(ja)
|
2009-04-01 |
2012-09-27 |
ミシェル テクノロジーズ,インコーポレイテッド |
被覆ステント
|
AU2010236825A1
(en)
|
2009-04-16 |
2011-09-15 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
CA2759015C
(en)
|
2009-04-17 |
2017-06-20 |
James B. Mcclain |
Stents having controlled elution
|
JP2012526144A
(ja)
|
2009-05-06 |
2012-10-25 |
ラボラトリー スキン ケア インコーポレイテッド |
活性物質−リン酸カルシウム粒子複合体を含む経皮送達組成物およびその使用方法
|
WO2011005421A2
(en)
|
2009-07-10 |
2011-01-13 |
Boston Scientific Scimed, Inc. |
Use of nanocrystals for a drug delivery balloon
|
EP2453938B1
(en)
|
2009-07-17 |
2015-08-19 |
Boston Scientific Scimed, Inc. |
Nucleation of drug delivery balloons to provide improved crystal size and density
|
SG178125A1
(en)
|
2009-08-03 |
2012-03-29 |
Univ Miami |
Method for in vivo expansion of t regulatory cells
|
EP2491032B1
(en)
|
2009-10-23 |
2014-04-16 |
Eli Lilly and Company |
Akt inhibitors
|
JP2013509444A
(ja)
|
2009-10-30 |
2013-03-14 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
がんの治療方法及び治療用組成物
|
US10391059B2
(en)
|
2009-11-11 |
2019-08-27 |
Rapamycin Holdings, Inc. |
Oral rapamycin nanoparticle preparations and use
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
MX2012005695A
(es)
|
2009-11-18 |
2012-06-13 |
Novartis Ag |
Metodos y composiciones para el tratamiento de tumores solidos y otras malignidades.
|
US8900603B2
(en)
|
2009-12-18 |
2014-12-02 |
Interface Biologics, Inc. |
Local delivery of drugs from self assembled coatings
|
CN102127092B
(zh)
*
|
2010-01-18 |
2013-04-17 |
东南大学 |
依维莫斯的制备
|
WO2011097103A1
(en)
|
2010-02-02 |
2011-08-11 |
Micell Technologies, Inc. |
Stent and stent delivery system with improved deliverability
|
US20130195919A1
(en)
|
2010-03-05 |
2013-08-01 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
UY33311A
(es)
|
2010-03-31 |
2011-10-31 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
EP2558092B1
(en)
|
2010-04-13 |
2018-06-27 |
Novartis AG |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
WO2011128405A1
(en)
|
2010-04-16 |
2011-10-20 |
Novartis Ag |
Combination of organic compounds
|
CA2797110C
(en)
|
2010-04-22 |
2020-07-21 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
MX342590B
(es)
|
2010-04-27 |
2016-10-05 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
|
GB201012889D0
(en)
|
2010-08-02 |
2010-09-15 |
Univ Leuven Kath |
Antiviral activity of novel bicyclic heterocycles
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
CA2805631C
(en)
|
2010-07-16 |
2018-07-31 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2012031236A1
(en)
|
2010-09-02 |
2012-03-08 |
Boston Scientific Scimed, Inc. |
Coating process for drug delivery balloons using heat-induced rewrap memory
|
GB201015411D0
(en)
|
2010-09-15 |
2010-10-27 |
Univ Leuven Kath |
Anti-cancer activity of novel bicyclic heterocycles
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
CN102464669B
(zh)
*
|
2010-11-17 |
2014-04-16 |
浙江海正药业股份有限公司 |
无定形依维莫司及其制备方法
|
CA2818225C
(en)
*
|
2010-11-19 |
2016-10-25 |
Biocon Limited |
Processes for preparation of everolimus and intermediates thereof
|
WO2012103959A1
(en)
|
2011-02-04 |
2012-08-09 |
Synthon Bv |
Process for making everolimus
|
PT2675451E
(pt)
|
2011-02-18 |
2015-10-16 |
Incyte Corp |
Terapia de combinação com inibidores mtor/jak
|
CN102174053B
(zh)
*
|
2011-03-09 |
2014-04-16 |
成都雅途生物技术有限公司 |
依维莫司的纯化方法
|
EP2683406B1
(en)
|
2011-03-11 |
2019-05-08 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-cd40 antibodies and uses thereof
|
EP2508525A1
(en)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
AU2012250010A1
(en)
|
2011-04-25 |
2013-10-10 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
US8809562B2
(en)
|
2011-06-06 |
2014-08-19 |
Chevron Phillips Chemical Company Lp |
Use of metallocene compounds for cancer treatment
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
WO2013012689A1
(en)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Drug delivery medical device
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
US20130028895A1
(en)
|
2011-07-27 |
2013-01-31 |
Gerald Wulf |
Exosome inhibiting agents and uses thereof
|
WO2013022458A1
(en)
|
2011-08-05 |
2013-02-14 |
Boston Scientific Scimed, Inc. |
Methods of converting amorphous drug substance into crystalline form
|
US9056152B2
(en)
|
2011-08-25 |
2015-06-16 |
Boston Scientific Scimed, Inc. |
Medical device with crystalline drug coating
|
CN102268015B
(zh)
*
|
2011-08-30 |
2013-08-28 |
成都摩尔生物医药有限公司 |
一种依维莫司的合成方法
|
GB201115665D0
(en)
|
2011-09-09 |
2011-10-26 |
Univ Leuven Kath |
Autoimmune and inflammatory disorder therapy
|
WO2013050419A1
(en)
|
2011-10-06 |
2013-04-11 |
Novartis Ag |
Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
EP2589383A1
(en)
|
2011-11-06 |
2013-05-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
FKBP subtype-specific rapamycin analogue for use in treatment of diseases
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
KR20160027218A
(ko)
|
2012-05-23 |
2016-03-09 |
에프. 호프만-라 로슈 아게 |
내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
|
CN102786534A
(zh)
*
|
2012-05-25 |
2012-11-21 |
上海现代制药股份有限公司 |
一种依维莫司的制备方法
|
ES2574522T3
(es)
|
2012-06-08 |
2016-06-20 |
Biotronik Ag |
Ésteres 40-O-hidrocarburo cíclico de rapamicina, composiciones y procedimientos
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
WO2014059295A1
(en)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
EP2919759A4
(en)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
|
CA2863243A1
(en)
*
|
2012-11-30 |
2014-06-05 |
Hangzhou Zylox Pharma Co., Ltd. |
Rafamycin analogs and methods for making same
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
KR20150136047A
(ko)
|
2013-01-09 |
2015-12-04 |
유니버시티 오브 마이애미 |
TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
|
JP6330024B2
(ja)
|
2013-03-12 |
2018-05-23 |
マイセル・テクノロジーズ,インコーポレイテッド |
生体吸収性バイオメディカルインプラント
|
US20160030401A1
(en)
|
2013-03-13 |
2016-02-04 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
|
EP4066841A1
(en)
|
2013-03-14 |
2022-10-05 |
University of Maryland, Baltimore |
Androgen receptor down-regulating agents and uses thereof
|
US10098871B2
(en)
*
|
2013-03-15 |
2018-10-16 |
Leslie B. Gordon |
Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
|
TW201503912A
(zh)
|
2013-03-19 |
2015-02-01 |
Novartis Ag |
包含癌莫事(everolimus)之醫藥組合物
|
EP2994758B1
(en)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
WO2014186532A1
(en)
|
2013-05-15 |
2014-11-20 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
CN105283553B
(zh)
|
2013-06-11 |
2021-06-25 |
克隆技术实验室有限公司 |
蛋白质富集的微泡及其制备和使用方法
|
US20160130280A1
(en)
*
|
2013-06-20 |
2016-05-12 |
Novartis Ag |
Alkylation with an alkyl fluoroalkyl sulfonate
|
CN103360411B
(zh)
*
|
2013-07-17 |
2015-09-30 |
成都雅途生物技术有限公司 |
依维莫司结晶提纯方法
|
SG11201600525XA
(en)
|
2013-08-12 |
2016-02-26 |
Tokai Pharmaceuticals Inc |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
US9580758B2
(en)
|
2013-11-12 |
2017-02-28 |
Luc Montagnier |
System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
|
EP3068435A1
(en)
|
2013-11-13 |
2016-09-21 |
Novartis AG |
Mtor inhibitors for enhancing the immune response
|
CN116478927A
(zh)
|
2013-12-19 |
2023-07-25 |
诺华股份有限公司 |
人间皮素嵌合抗原受体及其用途
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
KR101529963B1
(ko)
*
|
2013-12-27 |
2015-06-19 |
주식회사 종근당바이오 |
에베로리무스의 제조방법 및 이의 중간체
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
US10428331B2
(en)
|
2014-01-16 |
2019-10-01 |
Musc Foundation For Research Development |
Targeted nanocarriers for the administration of immunosuppressive agents
|
KR20160110963A
(ko)
|
2014-02-11 |
2016-09-23 |
노파르티스 아게 |
암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
|
EP3119425B1
(en)
|
2014-03-15 |
2020-09-23 |
Novartis AG |
Regulatable chimeric antigen receptor
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
CN103848849B
(zh)
*
|
2014-03-24 |
2016-02-24 |
上海医药工业研究院 |
依维莫司的制备工艺
|
AU2015237200A1
(en)
|
2014-03-27 |
2016-10-06 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
DK3129470T3
(da)
|
2014-04-07 |
2021-07-05 |
Novartis Ag |
Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
|
EP3131546B1
(en)
|
2014-04-16 |
2022-02-16 |
Rapamycin Holdings, Inc. |
Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs)
|
WO2015171723A1
(en)
|
2014-05-06 |
2015-11-12 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
|
CN105254646A
(zh)
*
|
2014-05-28 |
2016-01-20 |
上海博邦医药科技有限公司 |
一种制备依维莫司的方法
|
MX2016015569A
(es)
|
2014-06-02 |
2017-04-25 |
Children´S Medical Center Corp |
Metodos y composiciones para inmunomodulacion.
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
US9938297B2
(en)
|
2014-08-04 |
2018-04-10 |
Cipia Limited |
Process for the synthesis of everolimus and intermediates thereof
|
AU2015303835B2
(en)
|
2014-08-12 |
2020-04-09 |
Monash University |
Lymph directing prodrugs
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
GFRα−4キメラ抗原受容体を用いる癌の治療
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
BR112017002827B1
(pt)
|
2014-08-28 |
2023-04-18 |
Eisai R&D Management Co., Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
CN107073066B
(zh)
|
2014-09-11 |
2021-09-17 |
加利福尼亚大学董事会 |
mTORC1抑制剂
|
PL3194443T3
(pl)
|
2014-09-17 |
2022-01-31 |
Novartis Ag |
Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
ES2898849T3
(es)
|
2014-10-28 |
2022-03-09 |
Koushi Yamaguchi |
Medicamento para mejorar el síndrome de hipertensión inducida por el embarazo
|
WO2016066608A1
(en)
|
2014-10-28 |
2016-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
|
EP3473253A1
(en)
|
2014-10-29 |
2019-04-24 |
University Of Maryland |
Methods of treating age-related symptoms in mammals and compositions therefor
|
CN104478898A
(zh)
*
|
2014-11-18 |
2015-04-01 |
连云港恒运医药科技有限公司 |
依维莫司及其中间体的制备方法
|
WO2016135740A1
(en)
|
2015-02-23 |
2016-09-01 |
Natco Pharma Limited |
Process for preparing stable oral compositions of everolimus
|
MX2017010474A
(es)
|
2015-02-25 |
2017-11-28 |
Eisai R&D Man Co Ltd |
Metodo para suprimir el amargor de un derivado de quinoleina.
|
SI3097102T1
(en)
|
2015-03-04 |
2018-02-28 |
Gilead Sciences, Inc. |
A TOOL RECEPTOR MODULING 4,6-DIAMINO-PYRIDO (3,2-D) PYRIMIDINE COMPOUNDS
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
CA2982996A1
(en)
|
2015-04-17 |
2016-10-20 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
EP3297629A1
(en)
|
2015-05-20 |
2018-03-28 |
Novartis AG |
Pharmaceutical combination of everolimus with dactolisib
|
CN104892632B
(zh)
*
|
2015-06-03 |
2017-12-26 |
道中道(菏泽)制药有限公司 |
一种晶体形式的依维莫司及其制备方法
|
SG11201710198YA
(en)
|
2015-06-16 |
2018-01-30 |
Eisai R&D Man Co Ltd |
Anticancer agent
|
EP3109250A1
(en)
|
2015-06-23 |
2016-12-28 |
Synbias Pharma AG |
Method for the synthesis of rapamycin derivatives
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
SI3307322T1
(sl)
|
2015-09-04 |
2021-08-31 |
Primatope Therapeutics Inc. |
Humanizirana protitelesa proti CD40 in njihove uporabe
|
CA2997106C
(en)
|
2015-09-08 |
2024-06-04 |
Monash University |
Lymph directing prodrugs
|
US11357851B2
(en)
|
2015-11-11 |
2022-06-14 |
Novartis Ag |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
CN105566348A
(zh)
*
|
2015-12-31 |
2016-05-11 |
哈药集团技术中心 |
一种依维莫司的制备方法
|
ES2913073T3
(es)
*
|
2016-04-29 |
2022-05-31 |
Icahn School Med Mount Sinai |
Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis
|
JP6855470B2
(ja)
|
2016-05-27 |
2021-04-07 |
日本化薬株式会社 |
ラパマイシン又はその誘導体を含有する医薬組成物
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
US10370342B2
(en)
|
2016-09-02 |
2019-08-06 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
MX2019006090A
(es)
|
2016-11-23 |
2019-08-21 |
Novartis Ag |
Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos.
|
US20200081010A1
(en)
|
2016-12-02 |
2020-03-12 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
RS62456B1
(sr)
|
2016-12-22 |
2021-11-30 |
Amgen Inc |
Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
|
GB201701087D0
(en)
|
2017-01-23 |
2017-03-08 |
Univ Leuven Kath |
Novel prodrugs of mizoribine
|
EP3576736A4
(en)
*
|
2017-02-10 |
2020-08-26 |
Torcept Therapeutics Inc. |
RAPAMYCIN ANALOGUE
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
ES2871499T3
(es)
|
2017-05-15 |
2021-10-29 |
Bard Inc C R |
Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3644997A1
(en)
|
2017-06-26 |
2020-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
|
JP2020527044A
(ja)
|
2017-07-13 |
2020-09-03 |
アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) |
CD8+CD45RCLOW/−Treg集団の拡大増殖および免疫抑制能力を高めるための方法
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
CA3075046A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
CN108047265A
(zh)
*
|
2017-11-24 |
2018-05-18 |
成都海创药业有限公司 |
一种依维莫司中间体的制备纯化方法
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
WO2019157516A1
(en)
|
2018-02-12 |
2019-08-15 |
resTORbio, Inc. |
Combination therapies
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
AU2019262978B2
(en)
|
2018-05-01 |
2023-07-13 |
Revolution Medicines, Inc. |
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
|
JP7381492B2
(ja)
|
2018-05-01 |
2023-11-15 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Mtor阻害剤としてのc26-連結ラパマイシン類似体
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MA52501A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
EP3796948A4
(en)
|
2018-05-22 |
2022-03-02 |
Interface Biologics Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF MEDICATIONS TO A VESSEL WALL
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
JP7360396B2
(ja)
|
2018-06-01 |
2023-10-12 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及び同一物の使用方法
|
JP7357644B2
(ja)
|
2018-06-11 |
2023-10-06 |
アムジエン・インコーポレーテツド |
がんを処置するためのkras g12c阻害剤
|
WO2020050890A2
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
CN108676014A
(zh)
*
|
2018-06-15 |
2018-10-19 |
国药集团川抗制药有限公司 |
纯化依维莫司中间体的方法以及制备依维莫司的方法
|
CA3107352A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
JP2022510573A
(ja)
|
2018-07-23 |
2022-01-27 |
エンクリアー セラピーズ, インク. |
神経障害の治療方法
|
WO2020053125A1
(en)
|
2018-09-10 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
US20210349097A1
(en)
|
2018-10-05 |
2021-11-11 |
Eisai R&D Management Co., Ltd. |
Biomarkers for a combination therapy comprising lenvatinib and everolimus
|
US11541152B2
(en)
|
2018-11-14 |
2023-01-03 |
Lutonix, Inc. |
Medical device with drug-eluting coating on modified device surface
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
TWI844602B
(zh)
|
2018-12-20 |
2024-06-11 |
美商安進公司 |
Kif18a抑制劑
|
EP3898592A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CA3123042A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
CN113195000A
(zh)
|
2018-12-21 |
2021-07-30 |
第一三共株式会社 |
抗体-药物缀合物和激酶抑制剂的组合
|
KR102643707B1
(ko)
*
|
2019-01-22 |
2024-03-04 |
에오비안 파마슈티컬스, 인크. |
Mtorc 조절제 및 이의 용도
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
US20220176084A1
(en)
|
2019-04-08 |
2022-06-09 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
WO2020210634A1
(en)
|
2019-04-11 |
2020-10-15 |
Enclear Therapies, Inc. |
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
MX2021014126A
(es)
|
2019-05-21 |
2022-01-04 |
Amgen Inc |
Formas en estado solido.
|
TW202115056A
(zh)
|
2019-06-28 |
2021-04-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
JP2021008453A
(ja)
|
2019-07-02 |
2021-01-28 |
エフェクター・セラピューティクス,インコーポレーテッド |
翻訳阻害剤およびその使用
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
JP2022542394A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
AU2020325115A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
Pyridine derivatives as KIF18A inhibitors
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
JP7340100B2
(ja)
|
2019-10-28 |
2023-09-06 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Kras g12c変異型の小分子阻害薬
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
US20230192682A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
BR112022009390A2
(pt)
|
2019-11-14 |
2022-08-09 |
Amgen Inc |
Síntese melhorada de composto inibidor de kras g12c
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
IL294484A
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines Inc |
Dosage for shp2 inhibitor and methods for treating cancer
|
KR20220149534A
(ko)
|
2020-02-05 |
2022-11-08 |
퓨어테크 엘와이티, 아이엔씨. |
신경스테로이드의 지질 전구약물
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
AU2021308045B2
(en)
|
2020-07-15 |
2024-06-20 |
Taiho Pharmaceutical Co., Ltd. |
Pyrimidine compound-containing combination to be used in tumor treatment
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ras抑制劑
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
MX2023011004A
(es)
|
2021-03-19 |
2024-01-08 |
Trained Therapeutix Discovery Inc |
Compuestos para regular la inmunidad entrenada y métodos para usarlos.
|
CR20230570A
(es)
|
2021-05-05 |
2024-01-22 |
Revolution Medicines Inc |
Inhibidores de ras
|
TW202309053A
(zh)
|
2021-05-05 |
2023-03-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
JP2024516450A
(ja)
|
2021-05-05 |
2024-04-15 |
レボリューション メディシンズ インコーポレイテッド |
共有結合性ras阻害剤及びその使用
|
JP2024521979A
(ja)
|
2021-05-28 |
2024-06-04 |
大鵬薬品工業株式会社 |
Kras変異タンパク質の小分子阻害剤関連出願の相互参照
|
WO2023288046A1
(en)
|
2021-07-15 |
2023-01-19 |
President And Fellows Of Harvard College |
Compositions and methods relating to cells with adhered particles
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
WO2024167904A1
(en)
|
2023-02-07 |
2024-08-15 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders in combination with an mtor inhibitor
|
CN116813641A
(zh)
*
|
2023-06-09 |
2023-09-29 |
杭州华东医药集团康润制药有限公司 |
一种依维莫司的制备方法
|